Jefferies Bullish on Cubist's (CBST) CXA-201; Raises PT to $44
Tweet Send to a FriendGet Alerts CBST Hot Sheet
Price: $51.13 +2.32%
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade CBST Now!
Jefferies is increasing its price target on Cubist Pharmaceuticals (Nasdaq: CBST) from $36 to $44, while maintaining its Buy rating on the stock.
Jefferies comments that Cubist's CXA-201 "is potentially the most potent Gram-negative antibiotic in development, particularly for the most worrisome pseudomonas infections...CXA-201 is a combination of a new, rapidly-actericidal cephalosporin CXA-101 and marketed tazobactam. In vitro, CXA-101 showed ~99% pseudomonas susceptibility (vs. ~85% for 4th-generation cephalosporin, cefepime; ~84% for new carbapenem, doripenem) in addition to enhancing activity against beta-lactam-resistant Enterobacteriaceae strains."
Cubist's CXA-201 also has more pseudomona coverage, while Forst Labs (NYSE: FRX) CAZ-104 and CEF104 "have potency towards a relatively infrequent carbapenem-resistant strain of Klebsiella pneumoniae (KPC)."
The Phase III for CXA-201 is expected to commence before the end of the year. Phase II data is expected out in the third quarter.
Jefferies new price target consists of a fair value of about $38 per share for Cubicin and $6 per share for CXA-201, which is discounted at 11 percent annually. Jefferies estimates an acquisition price of $50 for Cubist.
For more analyst coverage on Cubist, click here. For a ratings summary, click here.
Cubist shares are trading 3 percent stronger in the early session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Jefferies comments that Cubist's CXA-201 "is potentially the most potent Gram-negative antibiotic in development, particularly for the most worrisome pseudomonas infections...CXA-201 is a combination of a new, rapidly-actericidal cephalosporin CXA-101 and marketed tazobactam. In vitro, CXA-101 showed ~99% pseudomonas susceptibility (vs. ~85% for 4th-generation cephalosporin, cefepime; ~84% for new carbapenem, doripenem) in addition to enhancing activity against beta-lactam-resistant Enterobacteriaceae strains."
Cubist's CXA-201 also has more pseudomona coverage, while Forst Labs (NYSE: FRX) CAZ-104 and CEF104 "have potency towards a relatively infrequent carbapenem-resistant strain of Klebsiella pneumoniae (KPC)."
The Phase III for CXA-201 is expected to commence before the end of the year. Phase II data is expected out in the third quarter.
Jefferies new price target consists of a fair value of about $38 per share for Cubicin and $6 per share for CXA-201, which is discounted at 11 percent annually. Jefferies estimates an acquisition price of $50 for Cubist.
For more analyst coverage on Cubist, click here. For a ratings summary, click here.
Cubist shares are trading 3 percent stronger in the early session.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Terex (TEX) Suffers from Weakness in Europe; Read-Through For Manitowoc (MTW)
- Goldman Sachs Starts Quintiles (Q) at Neutral
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
